Arrowhead Research Corp (ARWR) was Downgraded by Cantor Fitzgerald to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Cantor Fitzgerald advised their investors in a research report released on Nov 30, 2016.
Many Wall Street Analysts have commented on Arrowhead Research Corp. Arrowhead Research Corp was Downgraded by William Blair to ” Mkt Perform” on Nov 30, 2016. Shares were Reiterated by Chardan Capital Markets on Nov 10, 2016 to “Buy” and Lowered the Price Target to $ 8 from a previous price target of $10 .
On the company’s financial health, Arrowhead Research Corp reported $-0.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36. The company had revenue of $39.58 million for the quarter, compared to analysts expectations of $.05 million. The company’s revenue was down -68.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.27 EPS.
Arrowhead Research Corp closed down -0.07 points or -1.57% at $4.39 with 30,39,263 shares getting traded on Tuesday. Post opening the session at $4.46, the shares hit an intraday low of $4.37 and an intraday high of $4.5 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Oct 18, 2016, Douglas B Given (director) sold 12,000 shares at $6.72 per share price. According to the SEC, on Aug 24, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 20,000 shares at $8.00 per share price. On Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at $6.90 per share price, according to the Form-4 filing with the securities and exchange commission.
Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.